ARX vs ERIE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ERIE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARX and ERIE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARX and ERIE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Accelerant Holdings operates a data-driven risk exchange for specialty insurance. On one side are managing general agents (MGAs), the specialist underwriters who design and sell niche insurance products; on the other are risk capital partners such as insurers, reinsurers, and institutional investors who put up the capital to back those policies. Accelerant sits in the middle, using proprietary technology, data, and machine learning to match risk with capital, share high-fidelity underwriting data, and monitor portfolios. It earns a fixed-percentage, volume-based fee for sourcing, managing, and monitoring the business written through the exchange, which spans more than 500 specialty insurance products across 22 countries. The company reports through three segments: Exchange Services, MGA Operations, and Underwriting, and describes its model as capital-light because it aims to retain only a small share of the premium risk (roughly 9% in 2025) and pass the rest to third-party capital.

Full ARX guide

Erie Indemnity is the managing attorney-in-fact for the Erie Insurance Exchange, a reciprocal insurer owned by its policyholders. Rather than underwriting risk itself, Erie Indemnity provides sales, underwriting, policy issuance, billing, and administrative services to the Exchange and is paid a management fee set at up to 25 percent of the direct and affiliated assumed premiums the Exchange writes. This structure gives shareholders exposure to the growth of a large property, casualty, and life book across the eastern and midwestern United States without bearing the catastrophe and underwriting losses that sit inside the Exchange itself.

Full ERIE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARX drivers: The Thoma Bravo deal sets the price; Go-shop ended with no rival bid.
• ERIE drivers: Fee growth tied to Exchange premiums; Capital-light, high-margin model.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: With a signed all-cash agreement, the main risk is deal completion. For ERIE, erie Indemnity is almost entirely dependent on a single client, the Erie Insurance Exchange, so any deterioration in the Exchange's underwriting results, financial strength, or premium growth flows through to the management fee and dividend capacity.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARX if you believe its drivers more; ERIE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARX and ERIE guides.

ARX. Since August 13, 2026 ARX has been valued by the Thoma Bravo offer, not by earnings multiples. At $19.75 the shares trade about 2.5% below the $20.25 cash price, a spread that reflects the time until the expected first-half 2027 close and the chance the deal does not complete. Measures such as about 4 times TTM sales or 21 times forward earnings describe what the buyer is paying rather than where the stock is likely to trade before closing.

ERIE. At about $239.82 on October 16, 2026, Erie Indemnity trades around 22 times trailing earnings and about 17 times forward earnings, still above the broader property and casualty average, because the market pays up for a stable fee-based model. That premium has compressed from ERIE's own multi-year highs as the stock fell about 23% over a year while premium growth slowed to the low single digits and policy counts slipped. Consensus for the September quarter is EPS of about $3.41 on revenue of about $1.09 billion.

Headline figures (approximate, October 2026): ARX shows deal price (thoma bravo, all cash) $20.25 per share; enterprise value >$4 billion, share price / spread to deal $19.75 (Oct 16, 2026) / ~2.5%, expected close First half of 2027, revenue (ttm) ~$1.07 billion; ERIE shows revenue (ttm) ~$4.12B, revenue growth (latest qtr, yoy) ~2.8%, net income (ttm) ~$577M, q2 2026 diluted eps ~$3.45 (est. $3.35).

ARX and ERIE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARX and ERIE exposure against your real portfolio. It is not an investment adviser.